Dipraglurant Explained

Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu₅ receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).^{[1] [2] [3]} As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.^[4]

See also

• Basimglurant
• Fenobam
• Mavoglurant
• Raseglurant

External links

• Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics
• Dipraglurant-ER for dystonia - Addex Therapeutics

Notes and References

1. Book: Martinez A, Gil C . Emerging Drugs and Targets for Parkinson's Disease. 29 July 2013. Royal Society of Chemistry. 978-1-84973-617-6. 255–.
2. Book: Macor JE . Annual Reports in Medicinal Chemistry. 2012. Academic Press. 978-0-12-396492-2. 83–.
3. Book: Fox SH, Brotchie JM . Levodopa-Induced Dyskinesia in Parkinson's Disease. 8 October 2014. Springer. 978-1-4471-6503-3. 323–.
4. Web site: Dipraglurant-ER for dystonia . Addex Therapeutics . 2014-12-28 . 2014-12-28 . https://web.archive.org/web/20141228103548/http://www.addextherapeutics.com/rd/pipeline/dipra-er/ . dead .